Commodity Fingerprint: Genentech (POLIVY) – Signal Evidence & AI Readability

Genentech (POLIVY)

(https://polivy.com) 📸 Data Snapshot: May 30, 2026
Commodity Fingerprint — The Lens

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Commodity Fingerprint Detection of industry clichés/templates.
11 Impact Weight: 15 / 100
73% Reputation

The site follows a standard pharmaceutical ‘Patient Resource’ template, including the ubiquitous Doctor Discussion Guide and Financial Support blocks. While the drug-specific content is unique, the value proposition cliches like Every step… matters match common industry emotional mapping. It avoids extreme commodity penalties because the specific medical regimen (R-CHP) cannot be easily genericized.

Commodity Fingerprint is read from the page structure first: templated copy tends to repeat the same heading patterns and shapes seen across an industry. Below is the heading hierarchy captured, then the known cliché patterns for this industry to weigh it against.

🏗️ Semantic Structure — heading hierarchy & page identity (templated vs. distinct patterns)
HOMEPAGE POLIVY® (polatuzumab vedotin-piiq) for certain types of Diffuse Large B-Cell Lymphoma (https://polivy.com)
Title

POLIVY® (polatuzumab vedotin-piiq) for certain types of Diffuse Large B-Cell Lymphoma

Meta

Learn about POLIVY® (polatuzumab vedotin-piiq) plus R-CHP for adults with certain types of newly diagnosed diffuse large B-cell lymphoma (DLBCL). See full safety information.

H1 Plan your path with POLIVY®
H2 Make the most out of your next doctor’s visit
H2 Starting POLIVY
H2 Financial Support
H3 Every step of your first DLBCL treatment matters
H3 Every step of your first DLBCL treatment matters
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 What does POLIVY® treat?
H5 Important Safety Information and Indication
H5 Possible serious side effects
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED_BODY Important Safety Information | POLIVY® (polatuzumab vedotin-piiq) (https://polivy.com/newly-diagnosed/rchp/side-effects/important-safety-information.html)
Title

Important Safety Information | POLIVY® (polatuzumab vedotin-piiq)

Meta

Review the side effects and important safety information for POLIVY® (polatuzumab vedotin-piiq) plus R-CHP. See full safety information.

H1 Indication and Important Safety Information
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 What does POLIVY® treat?
H5 Possible serious side effects
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_HEADING_REPEATED_BODY Preparing for Treatment | POLIVY® (polatuzumab vedotin-piiq) (https://polivy.com/newly-diagnosed/rchp/taking-polivy/preparing-for-treatment.html)
Title

Preparing for Treatment | POLIVY® (polatuzumab vedotin-piiq)

Meta

Review tips on how best to prepare for treatment with POLIVY® (polatuzumab vedotin-piiq) plus R-CHP. See full safety information.

H1 Preparing for Treatment
H2 Tests
H2 Pretreatment medicines
H2 Financial and other support resources
H2 Tips to prepare for your treatment
H2 Questions To Ask Your Doctor
H2 Financial Support
H3 What you may expect
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 What does POLIVY® treat?
H5 POLIVY Infusion Checklist
H5 Important Safety Information and Indication
H5 Possible serious side effects
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
NAV_HEADER_REPEATED_BODY Is POLIVY® Right for Me? (https://polivy.com/newly-diagnosed/rchp/about-polivy/is-polivy-right-for-me.html)
Title

Is POLIVY® Right for Me?

Meta

Understand how POLIVY® (polatuzumab vedotin-piiq) plus R-CHP may help treat adults with certain types of newly diagnosed DLBCL. See full safety information.

H1 Is POLIVY® Right for Me?
H2 POLIVY is part of an FDA-approved treatment regimen for adults with certain types of newly diagnosed DLBCL
H2 Questions To Ask Your Doctor
H2 Financial Support
H3 This site is intended for US Healthcare Professionals
H3 Link to Third Party Site
H4 What does POLIVY® treat?
H5 Why have I been prescribed POLIVY plus R-CHP?
H5 What does R-CHP do?
H5 Important Safety Information and Indication
H5 Possible serious side effects
H5 I am a Healthcare Professional
H5 I am a Patient or Caregiver
🧭 Industry Context — common cliché & template patterns in Medical Devices, Pharma & Biotech to weigh against
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…